A case of sustained virologic response of HCV with telaprevir-based therapy in a patient with HIV and end stage kidney disease

International Journal of STD and AIDS

Volumn 25, Issue 11, 2014, Pages 830-832

  Slim, J ^a   Scangarello, N ^a   Samaha, P ^a   Dazley, J ^a  

^a SETON HALL UNIVERSITY   (United States)

Author keywords

end stage kidney disease; hepatitis C; HIV; telaprevir; treatment

Indexed keywords

ATAZANAVIR; PEGINTERFERON ALPHA2A; RIBAVIRIN; RITONAVIR; TELAPREVIR; ALPHA INTERFERON; ALPHA2B INTERFERON; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; OLIGOPEPTIDE; RECOMBINANT PROTEIN;

ADULT; AFRICAN AMERICAN; ANEMIA; ARTICLE; CASE REPORT; CHRONIC COUGH; COUGHING; DEPRESSION; END STAGE RENAL DISEASE; FATIGUE; HEMODIALYSIS; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FUNCTION; LIVER BIOPSY; LIVER FIBROSIS; MALE; MIXED INFECTION; SIDE EFFECT; THROMBOCYTOPENIA; WEIGHT REDUCTION; WHEEZING; COMPLICATION; DRUG COMBINATION; GENETICS; HEPACIVIRUS; HIV INFECTIONS; KIDNEY FAILURE, CHRONIC; LIVER CIRRHOSIS; TREATMENT OUTCOME; VIROLOGY;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; KIDNEY FAILURE, CHRONIC; LIVER CIRRHOSIS; MALE; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 84902804636     PISSN: 09564624     EISSN: 17581052     Source Type: Journal    
DOI: 10.1177/0956462414521164     Document Type: Article

References (16)

1. Sherman KE,Rouster SD,Chung RT, et al.Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US Adult AIDS Clinical Trials Group.Clin Infect Dis. 2002;34:831-837
2. Berenguer J,Alvarez-Pellicer J,Martin P, et al.Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with HIV and hepatitis C virus.Hepatology. 2009;50:407-413
3. Rodriguez-Torres M,Slim J,Bhatti L, et al.Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial.HIV Clin Trials. 2012;13:142-152
4. Sulkowski MS,Sherman KE,Dieterich DT, et al.Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 Infection in patients with HIV: a randomized trial.Ann Intern Med. 2013;159:86-96
5. Sulkowski M,Pol S,Mallolas J, et al.Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.Lancet Infect Dis. 2013;13:597-605
6. Knoll GA,Tankersley MR,Lee JY, et al.The impact of renal transplantation on survival in hepatitis C-positive end-stage renal disease patients.Am J Kidney Dis. 1997;29:608-614
7. Weber R,Sabin C,Friis-Møller N, et al.Liver-related deaths in persons infected with the HIV: the D:A:D study.Arch Intern Med. 2006;166:1632-1641
8. Macías J,Márquez M,Téllez F, et al.Risk of liver decompensations among human immunodeficiency virus/hepatitis c virus-coinfected individuals with advanced fibrosis: implications for the timing of therapy.Clin Infect Dis. 2013;57:1401-1408
9. Lacombe K,Valin N,Stitou H, et al.Efficacy and tolerance of telaprevir in HIV-hepatitis C virus genotype 1-coinfected patients failing previous antihepatitis C virus therapy: 24-week results.AIDS. 2013;27:1356-1359
10. Cachay ER,Wyles DL,Torriani FJ, et al.High incidence of serious adverse events in HIV-infected patients treated with a telaprevir-based hepatitis C virus treatment regimen.AIDS. 2013;27:2893-2897
11. Seden K,Back D,Khoo S.New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals.J Antimicrob Chemother. 2010;65:1079-1085
12. Seelig R,Renz M,Bottner C, et al.Hepatitis C virus infections in dialysis units: prevalence of RNA and antibodies to HCV.Ann Med. 1994;26: 45-52
13. Fabrizi F,Takkouche B,Lunghi G, et al.The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies.J Viral Hepat. 2007;14:697-703
14. Ghany MG,Strader DB,Thomas DL, et al.Diagnosis, management, and treatment of hepatitis C: an update.Hepatology. 2009;49:1335-1374
15. Glue P.The clinical pharmacology of ribavirin.Semin Liver Dis. 1999;19:17-24
16. Marcellin P,Forns X,Goeser T, et al.Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C.Gastroenterology. 2011;140:459-468